Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 85(5): 979-993, 2020 05.
Article
in En
| MEDLINE
| ID: mdl-32314030
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Transitional Cell
/
Urologic Neoplasms
/
Cyclin-Dependent Kinase Inhibitor p16
/
Deoxycytidine
/
DNA (Cytosine-5-)-Methyltransferase 1
/
Neoplastic Cells, Circulating
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2020
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Alemania